1. Yes. As described in the announcement no other adverse effects were observed.
2. The mice did not lose their fur. Having said this, this was not a model of alopecia.
3. It is progressing, but given the aim is to publish this work in one of the highest impact journals a great deal of work has to be done especially around the mechanism of action. While journal articles are nice to have, they are less important than progressing RC220.
Ann: Zantrene Protects Mouse Hearts from Chemotherapy Damage, page-113
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |